Study of Oral MRT-2359 in Selected Cancer Patients

计划入组 174 人 · 首次发布于 2022 年 9 月 19 日

AI-Driven Tumor Response Evaluation for Solid Tumors

计划入组 6,120 人 · 首次发布于 2026 年 7 月 6 日

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

计划入组 50 人 · 首次发布于 2014 年 4 月 10 日

MYC inhibitors (solid tumors)

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

BioLine Rx

Israel

Monte Rosa Therapeutics Announces Key Milestones for Molecular Glue Degraders in 2025

Monte Rosa Therapeutics Reports Promising MRT-8102 Cardiovascular Data and Prepares Updated MRT-2359 Cancer Results

PAS-004 Shows Favorable Safety and Early Efficacy in MAPK-Driven Solid Tumors